Introduction
In the United States, ovarian cancer is the leading cause of death from gynecologic neoplasms (1) . About 23,000 cases are diagnosed each year and 14,000 women die from the disease. The majority (%90%) of ovarian cancers are epithelial cancers arising from the human ovarian surface epithelium (HOSE), which is a simple squamous-to-cuboidal mesothelium covering the ovary.
Epidemiologic studies suggest dietary/environmental factors, such as high levels of meat consumption (2) , caffeine intake (3), and cigarette smoking (4) , are risk factors for ovarian cancer. In these instances, cytochrome P450 (CYP) 1A1 may play a major role in the metabolic activation of procarcinogens to carcinogens. For example, it is known that polycyclic aromatic hydrocarbons (PAH), by-products of incomplete combustion and pyrolysis of fossil fuels and organic matters, such as tobacco leaf, are direct carcinogens of HOSE cells (5) . Other environmental pollutants, such as the halogenated aryl hydrocarbon 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a by-product of some herbicides, are potent inducers of the enzyme (6) and may therefore exacerbate the metabolic activation of other procarcinogens to carcinogens. In a rat model, chronic treatment with TCDD promoted development of ovarian tumors (7) . An industrial accident in Seveso, Italy, in 1976 contaminated the area with TCDD and raised ovarian cancer incidence among female residents (8) . Similarly, endogenous factors, particularly estrogens, such as 17h-estradiol (E 2 ) and estrone (E 1 ), could be converted into catechol estrogens and other genotoxic metabolites via the action of CYP1A1 as well as CYP1B1 (9, 10) . These reactive metabolites are known carcinogens of mammary cells (10) and may also be involved in the neoplastic transformation of HOSE cells, which are exposed to high levels of follicular estrogens associated with ovulation (11, 12) . In this regard, women who carry polymorphic variants that confer higher CYP1A1 enzyme activity, such as the Ile/Val or Val/Val polymorphism in exon 7 (13) , are at higher risk for ovarian cancer (14, 15) . Additionally, positive interactions have been shown between tobacco smoking and CYP1A1 (MspI) polymorphism (16) as well as between high caffeine consumption and Ile/Val polymorphism (14) in ovarian cancer patients. Based on findings from these studies, we hypothesized that CYP1A1 plays a key role in mediating the carcinogenicity of specific endogenous and exogenous chemicals on the ovarian surface epithelium.
Alternative splicing is an important mechanism for generating proteomic complexity and functional diversity (17) . Removal of intron sequences from pre-mRNA is carried out by a ribonucleoprotein complex called a spliceosome. Most splicing events occur where the intron starts with GT and ends with AG, the so-called GT-AG rule. However, completion of the Human Genome Project has revealed other noncanonical splice pairs, including AT-AC (18) , along with novel spliceosomes (19) . New categories of alternative splicing events, including insertion of cryptic exons or excision of cryptic intron, production of exon/intron isoforms, and intron retention, have also been characterized (20, 21) . However, few of these new splicing mechanisms have been directly implicated in the pathogenesis of cancers.
In this study, we identified a novel CYP1A1 variant (CYP1A1v) that is formed via excision of an 84-bp cryptic intron within exon 2 of the gene. Thus, the goals of this study were (a) to compare the expression levels of CYP1A1wt and CYP1A1v in normal HOSE cell lines to those in ovarian cancer cell lines, (b) to investigate the expression pattern of CYP1A1 in 30 cases of clinical specimens, (c) to determine whether CYP1A1v is enzymatically active and compare its subcellular distribution with that of CYP1A1wt, and (d) to assess whether these isoforms possess transforming potentials when expressed stably in HOSE cell lines in the absence or presence of procarcinogens, such as benzo(a)pyrene (BaP, a prototype PAH) and estrogen (E 2 , an endogenous estrogen). Our findings showed that both CYP1A1 isoforms are overexpressed in ovarian cancer cell lines and clinical specimens. Importantly, CYP1A1v was found to be enzymatically active and exclusively localized to the mitochondria and nucleus. Forced expression of either isoforms induced anchorage-independent growth in HOSE cells, especially in the presence of BaP and E 2 . Collectively, these data provided the first evidence that CYP1A1 overexpression and alternative splicing could contribute to ovarian cancer initiation and progression. 23 ) were used in this study. These cells were cultured and maintained as reported previously (22) (23) (24) .
Materials and Methods
Clinical specimens. Human surgical ovarian tissues were collected by Z.J. at the Department of Pathology, University of Massachusetts Medical School (Worcester, MA) through routine procedures for histologic diagnosis. A total of 28 clinical specimens, including 24 ovarian neoplasms (18 serous adenocarcinomas, 3 mucinous adenocarcinomas, 2 borderline malignant mucinous tumors, and 1 benign serous cystadenoma), 3 normal ovaries, and 1 pancreatic metastasis to ovary, were included in this study. Paraffinembedded tissue sections were cut at 5 Am and mounted on SuperFrost Plus slides (Erie Scientific, Portsmouth, NH).
Immunohistochemistry. Epitope retrieval of 5 Am paraffin-embedded tissue sections was achieved through the use of antigen unmasking solution (Vector Laboratories, Burlingame, CA). A polyclonal rabbit anti-human CYP1A1 antibody (Human Biologics International, Scottsdale, AZ) with 1:100 dilution was applied. To show specificity of the antibody, preabsorption experiment was done using recombinant antigen purchased by Clontech (Palo Alto, CA). Routine and standard immunohistochemical procedures were carried out as reported previously (25) .
RNA isolation and reverse transcription-PCR analysis. Total RNA was isolated using TRI-reagent (Sigma, St. Louis, MO) according to protocols provided by the manufacturer. The forward primer of CYP1A1v recognized the boundary flanking the deletion of the novel variant of CYP1A1. Hot-start PCR using AmpliTaq Gold DNA polymerase (Perkin-Elmer, Norwalk, CT) was used in all amplification reactions. The PCR program for CYP1A1wt and CYP1A1v (CYP1A1-F 5V-AAGCACGTTGCAGGAGCTGATG-3V and CYP1A1-R 5V-ACATTGGCGTTCTCATCCAGCTGCT-3V), CYP1A1v (CYP1A1v-F 5V-GCCTAGTCAACCTGAATGCC-3V and CYP1A1v-R 5V-CGAAGGAA-GAGTGTCGGAAG-3V), and CYP1B1 (CYP1B1-F 5V-GGCTGGATTTGGA-GAACGTA-3V and CYP1B1-R: 5V-TCATCACTCTGCTGGTCAGG-3V) was 30 cycles of 1 minute at 94jC, 1 minute at 65jC, and 1 minute at 72jC, except that glyceraldehyde-3-phosphate dehydrogenase (GAPDH; GAPDH-F: 5V-CCACCCATGGCAAATTCCATGGCA-3VGAPDH-R: 5V-TCTAGACGGCAGGT-CAGGTCCACC-3V) cDNA was amplified at 26 cycles. Signal intensities of CYP1A1, CYP1A1v, and CYP1B1 amplimers were normalized to those of GAPDH to produce arbitrary units of relative abundance.
Direct DNA sequencing analysis. Reverse transcription-PCR (RT-PCR) products corresponding to CYP1A1 transcripts (wild-type and variant) were amplified using CYP1A1 primer sets listed above. The DNA bands of interest were excised and purified and subjected to radiolabeled primer cycle sequencing using the ThermoSequenase cycle sequencing kit (Amersham Biosciences Corp., Piscataway, NJ). Two separate rounds of sequencing were done to ensure reproducibility.
Western blot analysis. Nuclear, mitochondrial, microsomal, and cytosolic fractions were isolated according to the method of Le Ferrec et al. (26) . Protein concentrations of each fraction were measured by Bradford assay kit (Bio-Rad, Hercules, CA). Protein (50 Ag) was separated on 10% SDS-polyacrylamide gels and electroblotted onto polyvinylidene difluoride membranes. Methods and reagents used in Western blot analyses were described previously (27) .
Immunofluorescence staining. All four OVCA cell lines were grown on coverslips to 80% confluence and then stained with 2 Amol/L MitoTracker Red CM-H 2 XROS (Molecular Probes, Eugene, OR) in culture medium for 30 minutes. Methods of fixation, permeabilization, and antibody staining were followed as reported previously (28) with following modifications. Goat polyclonal human CYP1A1 antibody (Gentest, Woburn, MA) and chick anti-goat antibody tagged with Alexa Fluor 488 (Molecular Probes) were diluted to 1:100 and 1:1,000, respectively. The control experiment used human CYP1A1 supersomes (Gentest) preabsorbed primary antibody.
Ethoxyresorufin O-deethylase activity assay. Ethoxyresorufin Odeethylase (EROD) activity in different subcellular fractions from various OVCA cell lines was assessed according to the method of Burke et al. (29) . Reaction mixtures composed of 25 Ag protein and the NADPH regenerating system were employed. To determine maximal CYP1A1 activity, each sample was assayed concurrently with and without the addition of 1 unit CYP reductase (Sigma).
Generation of stable transfected human ovarian surface epithelium cell lines. Full-length CYP1A1wt and CYP1A1v cDNAs were amplified using Platinum Taq High Fidelity System (Invitrogen, Carlsbad, CA) and a specific pair of primers ( forward primer tgctagcATGCTTTTCCCAATCTC-CAT and reverse primer atttgcggccgcCTAAGAGCGCAGCTGCAT). To facilitate directional cloning of the PCR products, two restriction sites, NheI and NotI, were engineered to the 5V end of forward and reverse primers, respectively (as shown in small letters). PCR reactions were initiated at 94jC for 3 minutes and followed by 40 cycles of 1 minute at 94jC, 1 minute at 60jC, and 2 minutes at 68jC and continued to incubate at 68jC for 10 minutes at the end of cycle. PCR products were gel purified, digested, and cloned into pcDNA3.1 vector (Invitrogen) to generate pcDNA-1A1wt and pcDNA-1A1v vectors that express full-length transcripts of CYP1A1wt and CYP1A1v, respectively. Identity and reading frame of pcDNA-1A1wt and pcDNA-1A1v were confirmed by DNA sequencing (Macrogen, Inc., Seoul, Korea). Each of the immortalized HOSE cell lines (HOSE 301, 306, 636, and 642) was stably transfected with pcDNA-1A1wt and pcDNA-1A1v, separately, using LipofectAMINE Plus reagent (Invitrogen). Empty vector was also stably transfected into HOSE cell lines to serve as a control. Stable transfectants of HOSE cell lines carrying the empty vector, pcDNA-1A1wt, and pcDNA-1A1v were named as CTL, WT, and V, respectively. For each of the four HOSE lines, we generated their respective CTL, WT, and V derivatives.
Soft agar assay. Stable transfected HOSE cells were trypsinized, counted, and mixed with 0.4% Noble agar in complete medium with 5% charcoal-stripped serum (labeled as UT), charcoal-stripped medium with 1 Amol/L estrogen (labeled as E 2 ), or charcoal-stripped medium with 1 Amol/L BaP at a concentration of 1,250 cells/250 AL and then transferred into a 0.8% Noble agar precoated 24-well plates. Plates were incubated in 2Â medium for up to 4 weeks. The number of colonies formed in soft agar for each of the four HOSE cell lines transfected with the same vector was averaged and SDs were calculated.
In silico analyses. Extensive sequence analyses were carried out using nucleotide and protein BLAST programs provided by National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov). DNA sequences comparison was done using Clustalw from European Bioinformatics Institute (http://www.ebi.ac.uk/clustalw). Possible signal sequences and the hydrophilicity/hydrophobicity of CYP1A1 protein were analyzed using PSORTII (http://psort.ims.u-tokyo.ac.jp/form2.html) and SwissProt from Swiss Institute of Bioinformatics (http://us.expasy.org/), respectively.
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Statistical analyses. One-way ANOVA was used to detect significant differences among the various group means. A multiple range test using the Tukey-B procedure was employed to compare the individual group means. Significance was set at P < 0.05 or 0.01.
Results
Identification of a novel CYP1A1v in OVCA cells. In our initial experiments, when RT-PCR analyses were conducted using a primer set designed for CYP1A1, two PCR products of different sizes were detected in cDNA samples prepared from OVCA cells ( Fig. 1A) : a 387-bp product expected to be amplified from wild-type CYP1A1 transcripts and a smaller (303 bp) product. To minimize the chances of PCR artifacts, a more stringent annealing temperature (65jC) was used for all subsequent PCRs. The smaller-sized fragment was consistently amplified from all reactions under these conditions. DNA from the smaller band was isolated and sequenced, revealing that it could be derived from transcripts of a splicing variant. When compared with the wild-type transcript, the splicing variant has an 84-bp deletion in exon 2 ( Fig. 2A ). To our knowledge, its sequence had never been reported. We therefore concluded that it is a novel splicing variant, which we here called CYP1A1v. This sequence has since been deposited in Genbank with the assigned accession no. AY310359. A new set of specific primers designed to amplify CYP1A1v covering the variantspecific exon junction was used for subsequent semiquantification of the variant transcripts.
Overexpression of CYP1A1wt and the novel CYP1A1v in OVCA cells compared with human ovarian surface epithelium cells. Semiquantitative RT-PCR analyses showed that primary cultures of normal HOSE cells and immortalized HOSE cell lines expressed minimal levels of CYP1A1wt mRNA and CYP1A1v mRNA ( Fig. 1A and B) . In contrast, the four OVCA cell lines consistently showed overexpression of the two CYP1A1 transcripts compared with levels found in HOSE cell cultures. About a 5-fold increase in the CYP1A1wt mRNA and a 10-fold increase in CYP1A1v mRNA were observed in the OVCA cell lines on average (Fig. 1B) . In contrast, there was no observable difference in CYP1B1 mRNA expression levels among the various HOSE and OVCA cell lines.
Overexpression of CYP1A1 protein and atypical nuclear staining in human ovarian cancer specimens. A total of 27 clinical specimens, including 24 ovarian neoplasms (18 serous adenocarcinomas, 3 mucinous adenocarcinomas, 2 borderline malignant mucinous tumors, and 1 benign serous cystadenoma) and 3 normal ovaries were immunostained with a polyclonal rabbit anti-human CYP1A1 antibody to assess their expression of CYP1A1 proteins (Fig. 3 ). Strong cytoplasmic (nonnuclear) staining was restricted to the cancer cells of serous and mucinous adenocarcinomas but was more widespread in stromal cells ( Fig.  3A -C). Some cancer cells in these specimens showed both cytoplasmic and nuclear staining ( Fig. 3B ). CYP1A1 protein was also immunolocalized in the epithelial cells of borderline mucinous lesions (Fig. 3A) . The majority of serous and mucinous carcinoma cells showed immunopositivity in both nuclei and cytoplasmic staining ( Table 1) . Expression of cytoplasmic and nuclear CYP1A1 seems to decline concomitantly in types of carcinoma with lower malignancy. CYP1A1 immunonegativity was detected in benign serous cystadenoma ( Fig. 3D ) and normal human ovary. The one human tissue specimen of pancreatic metastasis to ovary in this study showed no detectable CYP1A1 protein expression (data not shown).
Overexpression of CYP1A1wt protein and CYP1A1v protein in ovarian cancer cell lines and exclusive localization of CYP1A1v in cell nucleus and mitochondria. Western blot analyses revealed that wild-type and variant CYP1A1 protein were expressed at very low levels in HOSE cells but were abundant in OVCA cell lines ( Fig. 4A ). Subcellular fractionation of OVCA cells revealed that the wild-type and variant proteins are localized in different cellular compartments. CYP1A1wt was principally associated with the microsomal fraction, whereas CYP1A1v resided predominantly in the nuclear and mitochondrial compartments of OVCA cells (Fig. 4A ). The unique subcellular distribution of CYP1A1v is specific, because no wild-type enzyme was colocalized to these fractions. Interestingly, neither protein was detected at any significant level in the cytosolic fraction. The unusual localization of CYP1A1v in the nucleus and mitochondria was also confirmed by immunofluorescence microscopy (Fig. 4B ). The fluorescence signals of CYP1A1 immunoreactivity (Fig. 4B , 2) completely coincided with signals from nuclear (blue; Fig. 4B , 1) and mitochondrial (red; Fig. 4B, 3) trackers in contrast to the results obtained with an Figure 1 . A, relative abundance of CYP1A1wt , CYP1A1v , CYP1B1 , and GAPDH transcripts in different normal, immortalized normal, and ovarian cancer cells. RT-PCRs were done on 1 Ag RNA using primer sets for corresponding genes. Representative fluorographs of the RT-PCR products. Bottom bands appearing exclusively in cancer cells were purified and sequenced. B, relative abundance of CYP1A1wt (white ), CYP1A1v (gray ), and CYP1B1 (black ) transcripts in HOSE and OVCA cells. Columns, mean relative abundance of gene transcripts from all primary cultures of normal and immortalized HOSE cells and those from the four OVCA cell lines [n = 12 (HOSE); n = 12 (immortalized HOSE); and n = 12 (OVCA)]; bars, SD. One-way ANOVA was applied to calculate the statistical significance of CYP1A1wt and CYP1A1v mRNA expression among HOSE, immortalized HOSE, and OVCA samples (P < 0.01).
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Cancer Res 2005; 65: (9) . May 1, 2005 antibody preparation preabsorbed with the antigen (Fig. 4B, 6) . The low levels of CYP1A1 signal observed in the nonmitochondrial compartment of the cytoplasm (Fig. 4B, 4 and 8-10) could be due to association of CYP1A1wt with the microsomes.
Computer-aided analysis of the CYP1A1v sequence. Analysis of the full-length sequence revealed that the 84-bp deletion is inframe and would not cause premature termination (Fig. 2B) , implying that the variant protein will have 28 fewer amino acid residues (amino acids 223-249; Fig. 2A ) in its NH 2 -terminal region than the wild-type protein. An extensive Genbank search found no previous report of the variant. However, a human EST clone (CB267342) in an adipocyte cDNA library was found to correspond to our reported sequence of the variant. This evidence strongly supports our belief that CYP1A1v exists in some other tissues and is not an artificial PCR product.
By comparing the sequence of CYP1A1v mRNA to that of the wild-type transcript, eight possible splice junction pairs were recognized (i.e., the dinucleotides upstream and downstream of the splice site could be CC-TC, CT-CC, TG-CC, GA-CT, AA-TG, AT-GA, TA-AA, or AA-AT; Fig. 2C ). However, none of these obeyed the GT-AG rule (30) , suggesting that a noncanonical splice site is responsible for alternative splicing of the CYP1A1 pre-mRNA. Moreover, among the eight possible sites, because only one splice junction pair, AA-AT, has been suggested to exist by statistical analysis of all annotated genes in the mammalian genome (18) , it may be the pair involved in splicing of this variant.
To investigate why only the CYP1A1v (not the wild-type protein) is targeted to the nucleus and mitochondria, an extensive in silico search of possible signaling peptides was done. A putative bipartite basic nuclear localization signal (NLS) was identified in the CYP1A1 amino acid sequence from residues 341 to 357 (RKIQEELDT-VIGRSRRP; Fig. 2A) , which matches the consensus motif (K/R) 2 X 10 -12 (K/R) 3 of nucleoplasmin (31) . However, these searches failed to identify a mitochondrial matrix-targeting signal, most commonly composed of positive charge and hydroxylated residues (32) , in the CYP1A1v. Of interest, hydrophobicity analysis revealed a decrease in the overall hydrophobicity in the NH 2 -terminal region of CYP1A1, most markedly around amino acids 230 to 260, which encompasses the deleted region (33) . Thus, perturbation in this general area may result in the formation of a functional mitochondrial targeting signal.
According to a recent molecular modeling study of human CYP1A1 (34), both resorufins and BaP are primarily stabilized by hydrophobic interactions in the substrate binding pocket. Within this substrate binding pocket, two key amino acid residues in helix F responsible for substrate stabilization (amino acids 224 and 228; Fig. 2A ) were found to be deleted from the CYP1A1v. Loss of these amino acids may result in alterations in substrate specificity and/or binding affinity in the variant protein.
CYP1A1v in both nucleus and mitochondria is active in ethoxyresorufin O-deethylase assay. To determine whether the mitochondria-and nucleus-localized CYP1A1 protein, presumably derived from the CYP1A1v, is catalytically active, the EROD assay was done after subcellular fraction of ovarian cancer cell lines (OVCA 429, 432, and 433) in the presence and absence of exogenous CYP oxidoreductase. The enzyme activity found in subcellular fractions of each cell lines were determined and averaged (Fig. 5 ). In the absence of exogenous CYP oxidoreductase, the highest EROD activity was detected in the nuclear fraction followed by the mitochondrial and microsomal fractions, whereas the cytosolic fraction was devoid of EROD activity. In the presence of extra CYP oxidoreductase, significantly higher levels (3-to 4-fold increases) of EROD activities were found in all fractions. The greatest increase was observed in the microsomal fraction followed by the mitochondrial and nuclear fractions. Under this condition, a low level of cytosolic EROD activity was also detected. We noticed that NAPDH oxidoreductase plays a greater role in enhancing the enzyme activity of CYP1A1wt and CYP1A1v in ovarian cancer cell lines. It seems that the activities of both CYP1A1wt and CYP1A1v are limited by low levels of oxidoreductase activity in ovarian cancer cells when compared with TCDD-stimulated MCF-7 cells (data not shown). Because we have shown exclusive localization of the CYP1A1v in the mitochondria and nucleus by Western blotting, together with previously reported association of CYP1A1wt with the microsomes (35) , the EROD data now strongly support the notion that the CYP1A1v is catalytically as active as CYP1A1wt.
CYP1A1wt and CYP1A1v are both involved in benzo(a)pyyrene-or 17B-estradiol-induced cellular transformation. This experiment sought to determine (a) whether overexpression of CYP1A1wt and CYP1A1v in HOSE cells also results in their protein products localized to different cellular compartment, (b) 
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www.aacrjournals.org whether overexpression of CYP1A1wt or CYP1A1v induces neoplastic transformation per se in HOSE cells, and (c) whether overexpression of the enzyme mediates cellular transformation caused by an endogenous/exogenous procarcinogen. The soft agar colony formation assay was used to measure acquisition of anchorage-independent growth potential in the four HOSE cell lines (HOSE 301, 306, 636, and 646), each stably transfected with empty pcDNA3.1 (HOSE-CTL), pcDNA-1A1wt (HOSE-WT), or pcDNA-1A1v (HOSE-V). BaP, a major PAH produced during cigarette smoking (36) , was used as a prototype exogenous environmental procarcinogen. E 2 , the major circulating and follicular estrogen, was chosen for our study because ovarian surface epithelial (OSE) cells are often exposed to high levels of this steroid around ovulation or when trapped in the stroma as inclusion cysts (11) . Both BaP and E 2 are the known substrates for CYP1A1, and their metabolites are carcinogenic (9, 10, 37) .
All four HOSE-CTL cell lines expressed no detectable CYP1A1wt
or CYP1A1v mRNA as shown by semiquantification of the transcripts by RT-PCR (Fig. 6A ). As expected, HOSE-V cell lines expressed high levels of CYP1A1v transcript and no detectable CYP1A1wt mRNA (Fig. 6A, top) . Surprisingly, HOSE-WT cell lines, in addition to high levels of CYP1A1wt mRNA, also expressed detectable levels of CYP1A1v transcripts, likely products of alternative splicing of the wild-type transcript (Fig. 6A, middle) . Exposure of HOSE cell lines (CTL, WT, or V) to BaP and E 2 did not alter expression levels of CYP1A1wt, CYP1A1v, or CYP1B1.
Two approaches were used to determine whether HOSE-WT and HOSE-V cell lines overexpressed the CYP1A1s that exhibited extraendoplasmic reticulum (ER) localization. EROD assays were done on subcellular fractions of three types of stable transfected HOSE cell lines (HOSE-CTL, HOSE-WT and HOSE-V) and revealed the following: (a) the enzyme activities of CYP1A1 were elevated in both HOSE-WT and HOSE-V cell lines when compared with HOSE-CTL cells, (b) the enzyme activities were predominantly detected in the nuclear fractions (Fig. 6B) , and (c) little to no enzymatic activities were present in the mitochondrial fraction. Results from immunofluorescence assays (data not shown) confirmed this observation. Of interest to note, the quantity of mitochondria in those HOSE cell lines was extremely low when compared with OVCA cells (data not shown).
As shown in Fig. 6C , the soft agar assay revealed that (a) exposure of HOSE cell lines transfected with the empty vector (HOSE-CTL) to the procarcinogens BaP and E 2 did not cause significant increases in soft agar colony formation potentials in these cell lines, (b) stable transfection of HOSE cell lines with pcDNA-1A1wt or pcDNA-1A1v vector significantly increased their soft agar colony formation potentials by 100% to 200% (P < 0.01) in the absence of BaP or E 2 exposure, and (c) after exposure to BaP or E 2 HOSE-WT and HOSE-V cell lines exhibited additional increases in soft agar colony formation potentials; the effect of E 2 was greater than that of BaP in both kinds of stable transfectants and greatest in HOSE-WT cell lines.
Discussion
In this study, we identified a novel CYP1A1v produced by a splicing event that involves an excision of an 84-bp cryptic intron. CYP1A1v, which is enzymatically active and is uniquely and exclusively located in the nucleus and the mitochondria instead of in the ER, where the wild-type enzyme resides. Importantly, when HOSE cells were engineered to overexpress CYP1A1wt, this alternative splicing mechanism generated CYP1A1v from the mature wild-type transcript. Hence, an overall increase in CYP1A1 gene expression would give rise to both transcripts and proteins and extend cellular localization of the enzyme to new cellular compartments. Of significance, we detected higher levels of CYP1A1wt and CYP1A1v mRNA in four ovarian cancer cell lines when compared with primary cultures of normal HOSE cells and four immortalized HOSE cell lines, which express little or no CYP1A1 transcripts. Immunocytochemistry revealed overexpression of the enzyme in various types of ovarian cancers with both cytosolic and nuclear localization. Comparable levels of CYP1A1 activity, as measured by the EROD assay, were found in nuclear, mitochondrial, and microsomal fractions of OVCA cells but not in HOSE cells. Enzyme activity in all three compartments depended on NADPH regeneration. Further investigation showed acquisition of anchorage-independent growth in HOSE cells engineered to stably overexpress exogenous CYP1A1wt or CYP1A1v. On exposure of these cells to BaP or E 2 (especially to the steroid, E 2 ), further enhancement of anchorage-independent growth was observed. Taken together, these findings provide strong support for an essential role of CYP1A1 in neoplastic transformation of HOSE cells likely via metabolic activation of exogenous/endogenous procarcinogens and utilization of a unique alternative splicing mechanism to broaden the distribution of the enzyme to critical organelles. The overall hypothesis of this study has been summarized in Fig. 7 . Figure 4 . A, Western blot analysis of CYP1A1 in various subcellular fractions of HOSE and OVCA cells. Representative experiment. nucl , mito , mic , and cyto, fractions isolated from nucleus, mitochondria, microsomes, and cytosol, respectively. CYP1A1v is uniquely found in nucleus and mitochondria, whereas CYP1A1wt resides in microsomes. B, immunofluorescence staining. 1 and 5 (blue ), 4V,6-diamidino-2-phenylindole (DAPI ) staining; 2 (green ), anti-CYP1A1 antibody staining; 6, antigen preabsorbed anti-CYP1A1 antibody staining; 3 and 7 (red), MitoTracker Red staining; 4 and 8, composite images of 1 to 4 and 5 to 8, respectively; 9, magnified version of 4 showing the differential staining of CYP1A1 in mitochondria (orange ) in white arrowheads and microsomes (green ) in yellow arrowheads; 10, magnified version of negative control (8 ) using preabsorbed antibody. Splicing events have been characterized and divided into four different categories (20, 21) : insertion of cryptic exons or excision of crytic introns, production of exon/intron isoforms, and intron retention. In our study, an 84-bp cryptic intron is spliced from exon 2 of CYP1A1wt, possibly via an AA-AT splice junction pair, as suggested by our in silico analysis. This is a noncanonical splice pair, because >96% of pre-mRNA splicing use the conservative GT-AG pair (18) . The involvement of noncanonical splice junction pairs may be due to poorly conserved 5V and 3V splice sites and/or many cryptic splice sites (38) . Recent findings suggest that introns flanked by another noncanonical AT-AC pair are excised by a spliceosome composed of nonclassic types of small nuclear ribonucleoproteins (19) . Interestingly, when HOSE cells are stably transfected with a CYP1A1wt expression vector, we found that CYP1A1v coexisted with the wild-type transcript. This finding indicates that the mature transcripts of CYP1A1wt are susceptible to this splicing event. Thus, induction of CYP1A1wt overexpression in normal OSE cells by xenobiotic/endobiotics or physiologic stresses could yield both transcripts along with their protein products and might extend the coverage of enzyme to new cellular organelles, where they may contribute to an imbalance in activation/detoxification of procarcinogens. This splicing event may exist in tissues other than the OSE because we also observed expression of CYP1A1v mRNA in breast and prostate cancer cells. 5 Although a few early reports detected CYP1A1-like enzyme activity in cell nucleus (39) and mitochondria (40) in rodent models, the enzyme identities remain unclear. CYP1A1v is the first human CYP1A1v to be identified and characterized at both molecular and biological levels. Thus, alternative splicing of CYP1A1 could be considered a mechanism for targeting the enzyme to extra-ER locales. Computational analyses identified a putative bipartite basic NLS, which is masked in the CYP1A1wt. One can speculate that removal of the cryptic intron results in the activation of this NLS and nuclear targeting of CYP1A1v. However, we cannot yet explain the acquisition of the mitochondrial matrix targeting signal via deletion of the 84-bp region, except to hypothesize that the deletion induces an increase in hydrophobicity in the NH 2 terminus of the molecule and creates a mitochondrial targeting signal (32) for the variant enzyme. Most of the CYP enzymes residing in the ER have been shown to depend on NADPH-oxidoreductase for electron transfer (41) , and their activities are enhanced in the presence of an NADPH regenerating system. Here, we found that the EROD activity in the mitochondrial, nuclear, and microsomal fractions of ovarian cancer cells were all elevated in the presence of exogenous NADPH-oxidoreductase, suggesting that comparable cofactor requirements exist between the wild-type and the variant enzyme.
Our results strongly support a role for aberrant expression of CYP1A1 in ovarian carcinogenesis. Exposure of HOSE cells to BaP or E 2 per se did not induce increased expression of the enzyme. In the absence of CYP1A1 expression, these two procarcinogens were ineffective in inducing an anchorage-independent growth phenotype in these cells. In marked contrast, overexpression of CYP1A1wt or CYP1A1v in HOSE cell lines significantly increased anchorageindependent growth potentials of HOSE cells even in the absence of BaP or E 2 . Elevated levels of CYP1A1wt and/or CYP1A1v expression probably had caused neoplastic transformation via activation of procarcinogens existing in the culture medium per se. Exposing the 5 Unpublished data. Figure 6 . A, expression of CYP1A1wt , CYP1A1v , and CYP1B1 in a representative HOSE cell line stably transfected with the empty vector (CTL), the expression vector for CYP1A1wt (WT ), or one for CYP1A1v (V) after a 24-hour treatment with 1 Amol/L estrogen (E2 ), 1 Amol/L BaP, or vehicle (Untreated ), respectively. RT-PCR was done using the CYP1A1 primer pair that amplifies both wild-type (solid arrowhead) and variant (close arrowhead) CYP1A1 transcript (CYP1A1, top ). The CYP1A1v -specific primer pair was used to amplify the variant only (CYP1A1v, middle ) and the CYP1B1 -specific primer set for the CYP1B1 mRNA (CYP1B1, bottom ). B, HOSE cell lines stably transfected with empty vector (HOSE-CTL, white columns ), the CYP1A1wt expression vector (HOSE-WT, gray columns ), or the CYP1A1v expression vector (HOSE-V, black columns) were subfractionated by differential centrifugation. Different fractions of HOSE-CTL, HOSE-WT, and HOSE-V cell extracts were obtained and EROD assay was done. Experiments were done as suggested in Materials and Methods. Average fold of change and experiment was done in triplicate. C, anchorage-independent growth potentials were measured as number of colonies formed in soft agar for HOSE cell lines stably transfected with empty vector, the CYP1A1wt expression vector, or the CYP1A1v expression vector. White , gray , and black columns, results for HOSE cell lines stably transfected with the empty pcDNA3.1, pcDNA-1A1wt, or pcDNA-1A1v vector, respectively. Untreated , E2 , and BaP, three types of stable transformed HOSE cell lines in soft agar exposed to medium alone, medium with 1 Amol/L E 2 , or medium with 1 Amol/L BaP, respectively. Columns, mean number of colonies formed in soft agar from all stable transfectants from all four HOSE cell lines; bars, SD. One-way ANOVA was applied to calculate the statistical significance among different groups. stable transfectants to BaP or E 2 increased soft agar colony formation in both HOSE-WT and HOSE-V cell lines. Of interest is the marked elevation of soft agar colony formation in HOSE-WT cell cultures exposed to E 2 when compared with HOSE-V cell lines. In contrast, BaP elicited roughly the same response in both types of stable transfectants. Because the overexpression of CYP1A1 in HOSE-WT and HOSE-V cell lines were localized primarily in nuclear compartment possibly due to low abundance of mitochondria in these cell lines, we suggest that nuclear localization of CYP1A1 is sufficient to mediate BaP-induced neoplastic transformation, whereas the E 2 -induced transformation may involve the presence of the enzyme in multiple subcellular organelles. Indeed, BaP carcinogenicity is believed to be mediated by the translocation of the procarcinogen to the cell nucleus followed by formation of the mutagenic metabolite BaP-7,8-diol 9,10-epoxide and DNA adducts, which in turn initiate mutagenesis (42, 43) .
On the contrary to BaP, estrogen carcinogenicity is much more complex and involves multiple phase I and II enzymes with different subcellular locales. Estrogens are converted to catecholestrogens (2-OH and 4-OH estrogens) and estrogen quinones, which are genotoxic, via CYP1A1 and CYP1B1 metabolic activation (9, 10) . Catechol-O-methyltransferase catalyzes the methylation of catechol estrogens to methoxyestrogens, which may reduce the potential for genomic damage and suppress cell proliferation via enhancement of 2-MeOE2 formation (44, 45) . Aberrant or altered expression of these estrogen metabolic enzymes is implicated in the initiation of human breast and endometrial tumors (9, 10, 46, 47) . Analogous information has been scarce for ovarian carcinogenesis. The human ovarian epithelium is routinely exposed to high levels of estrogens such as those produced during the follicular phase of each female cycle. Alternatively, the ovarian epithelium is exposed to abnormal levels of stromal estrogens with the formation of inclusion cysts, which in fact have been proposed as the origin of epithelial ovarian cancer (48) . In general, CYP1A1 produces mostly 2-OH estrogens, but a significant amount of 4-OH estrogens is generated simultaneously (49) . It has been shown that 4-OH estrogens are more carcinogenic than 2-OH estrogens in a mammary epithelial cell model (10) . Whether a similar scenario exists for OSE remains to be investigated in future experiment.
In summary, we here provide the first evidence that CYP1A1 is overexpressed in ovarian cancer cell lines and ovarian cancers. We also report the identification of a novel variant of CYP1A1 that is enzymatically active and resides exclusively in cell nucleus and mitochondria. Our data suggest that a noncanonical splice group is responsible for the removal of a cryptic intron from the CYP1A1 transcript. These findings raise the possibility that alternative splicing underlies increased functional diversity of CYP1A1 by increasing its subcellular coverage. They also suggest that chronic or repeated induction of CYP1A1 expression in HOSE cells would result in expression of the enzyme in multiple cellular organelles, leading to an imbalanced detoxification-activation homeostasis of xenobiotics/endobiotics, a mechanism long suspected to induce neoplastic transformation. Figure 7 . Schematic diagram summarizing the hypothesis of this study. In normal HOSE cells, the expression level of CYP1A1wt (diamond ) is low or undetectable. On exogenous (environmental factors) or endogenous (hormone factors) stimuli, CYP1A1wt can be significantly induced in HOSE cells. Some of the CYP1A1wt transcripts can be partially converted into CYP1A1v (broken diamond ) by alternative splicing via cryptic intron excision. The protein products of CYP1A1v mRNA are targeted to nucleus and mitochondria instead of microsomes (ER) where CYP1A1wt resides. Both CYP1A1wt and CYP1A1v can metabolize various kinds of procarcinogens into highly reactive carcinogens, which in turn attack protein and DNA within their compartments. As a result of DNA adduct formation, DNA mutations accumulate and eventually impair genome stability. HOSE can be finally transformed with more cancer phenotypes. With the perpetual stimulation of activated carcinogens, transformed cells may progress to more advanced stage.
